Sharekhan's research report on Ipca Laboratories
Ipca’s board is set to discuss integration of Bayshore Pharmaceuticals’ generics business into Unichem Pharma US. Bayshore’s integration would enhance growth prospects, drive international revenue, on recent regulatory approvals for US manufacturing sites. Ipca’s investments in biologics and plans to revitalize its CDMO initiatives suggest significant growth potential, supporting our price target of 1734. Ipca is investing in biologics and plans to revitalize its contract drug development and manufacturing (CDMO) ambitions, which were previously affected by regulatory issues with the U.S. FDA.
Outlook
The stock currently trades at 39x and 30x based on its FY26E and FY27E EPS estimates of 37.77 and 49.52, respectively.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
